Clarametyx Home Revenue and Competitors

Location

#1179

Growjo Ranking

Fintech

Industry

Estimated Revenue & Valuation

  • Clarametyx Home's estimated annual revenue is currently $3.6M per year.(i)
  • Clarametyx Home's estimated revenue per employee is $134,815
  • Clarametyx Home's total funding is $44M.

Employee Data

  • Clarametyx Home has 27 Employees.(i)
  • Clarametyx Home grew their employee count by 13% last year.

Clarametyx Home's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Co-founder & Chief Scientific OfficerReveal Email/Phone
3
Scientific Co-Founder & Scientific Advisory Board Co-ChairReveal Email/Phone
4
Co-founder & Board Co-ChairReveal Email/Phone
5
VP, Clinical OperationsReveal Email/Phone
6
VP, Clinical OperationsReveal Email/Phone
7
Director Clinical Development and Portfolio StrategyReveal Email/Phone
8
Director, Project OperationsReveal Email/Phone
9
Chief Operating OfficerReveal Email/Phone
10
Operations Program ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0M1-67%$3MN/A
#2
$379.7M0N/A$30.5MN/A
#3
$6.6M58-3%$3.4MN/A
#4
$14M108-3%$40.4MN/A
#5
$0.6M90%N/AN/A
#6
$65.9M399-29%$609.1MN/A
#7
$0M20%$10MN/A
#8
$72M443-7%N/AN/A
#9
$14.7M113N/AN/AN/A
#10
$109M67115%N/AN/A
Add Company

What Is Clarametyx Home?

Clarametyx Biosciences Inc. is a preclinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

keywords:N/A

$44M

Total Funding

27

Number of Employees

$3.6M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Clarametyx Home News

2022-03-30 - CARB-X Awards Clarametyx Biosciences $3.89 Million in ...

(“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.8M27-56%$44M
#2
$2.7M27N/AN/A
#3
$4.2M270%N/A
#4
$4.2M27-29%N/A
#5
$6.2M27-13%N/A